ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: INFO17

Mayo Clinic Translational Polycystic Kidney Disease Center (MTPC)

Session Information

  • Informational Posters
    November 03, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
    Abstract Time: 10:00 AM - 12:00 PM

Category: Genetic Diseases of the Kidneys

  • No subcategory defined

Authors

  • Sussman, Caroline R., Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Senum, Sarah R., Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Gregory, Adriana, Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Li, Xiaoyan, Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Mann, Zoey, Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Sieben, Cynthia J., Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Yang, Hana, Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Kennedy, Kristian M., Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Romero, Michael F., Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Chebib, Fouad T., Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Irazabal, Maria V., Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Li, Xiaogang, Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Erickson, Bradley J., Mayo Clinic Department of Radiology, Rochester, Minnesota, United States
  • Hu, Jinghua, Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Kline, Timothy L., Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Torres, Vicente E., Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Harris, Peter C., Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
Description

The Mayo Clinic Translational PKD Center is comprised of faculty and staff with expertise spanning basic research through clinical trials. Our collaborative efforts provide insights into PKD pathomechanisms for biomarker, therapy, and prognostics development, and we share materials, resources, and expertise to support academic and industry-sponsored PKD research. Our goal is to promote basic research breakthroughs and facilitate their translation into clinical practice. The Center has three areas of focus: 1) Genetics, Epigenetics and Metabolomics (GEM), 2) Model Systems, and 3) Imaging. Within GEM, our expertise and resources include genetic characterization of PKD patients and elucidation of epi/genetic and cellular mechanisms of PKD for therapy and biomarker discovery. We maintain a Cystic Kidney and Liver Disease Biobank that collects and shares PKD patient materials. With PKD Foundation support, we maintain the PKD Foundation ADPKD Mutation Database, which collates and evaluates the significance of variants in the PKD1 and PKD2 genes to aid diagnostics and categorization of patient populations. Within Model Systems, we maintain and develop PKD models in C. elegans, zebrafish, rodents, and pig. Established models in C. elegans, zebrafish, and rodents are available for sharing or collaborative projects. Standardized protocols for zebrafish and murine preclinical testing are available for examining novel therapeutics. Highly conserved C. elegans and zebrafish models are options for higher throughput/lower cost drug screening. Within Imaging, we continue to develop advanced protocols for preclinical and clinical imaging (3D ultrasound, CT, quantitative MR), and image processing (radiomics, machine learning, and deep learning analysis). Standardized protocols are available for accurate and automated analysis of organ volume, cyst number, and size, providing enhanced patient-specific image-based metrics. We support numerous trainees spanning undergraduate through junior faculty, including Summer Undergraduate Research Fellowships available through an R25 grant and Postdoctoral Fellowships available through a T-32 grant.

Abstract: INFO17

Mayo Clinic Translational Polycystic Kidney Disease Center (MTPC)

Session Information

  • Informational Posters
    November 04, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
    Abstract Time: 10:00 AM - 12:00 PM

Category:

  • No subcategory defined

Authors

  • Sussman, Caroline R., Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Senum, Sarah R., Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Gregory, Adriana, Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Li, Xiaoyan, Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Mann, Zoey, Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Sieben, Cynthia J., Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Yang, Hana, Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Kennedy, Kristian M., Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Romero, Michael F., Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Chebib, Fouad T., Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Irazabal, Maria V., Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Li, Xiaogang, Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Erickson, Bradley J., Mayo Clinic Department of Radiology, Rochester, Minnesota, United States
  • Hu, Jinghua, Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Kline, Timothy L., Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Torres, Vicente E., Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Harris, Peter C., Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
Description

The Mayo Clinic Translational PKD Center is comprised of faculty and staff with expertise spanning basic research through clinical trials. Our collaborative efforts provide insights into PKD pathomechanisms for biomarker, therapy, and prognostics development, and we share materials, resources, and expertise to support academic and industry-sponsored PKD research. Our goal is to promote basic research breakthroughs and facilitate their translation into clinical practice. The Center has three areas of focus: 1) Genetics, Epigenetics and Metabolomics (GEM), 2) Model Systems, and 3) Imaging. Within GEM, our expertise and resources include genetic characterization of PKD patients and elucidation of epi/genetic and cellular mechanisms of PKD for therapy and biomarker discovery. We maintain a Cystic Kidney and Liver Disease Biobank that collects and shares PKD patient materials. With PKD Foundation support, we maintain the PKD Foundation ADPKD Mutation Database, which collates and evaluates the significance of variants in the PKD1 and PKD2 genes to aid diagnostics and categorization of patient populations. Within Model Systems, we maintain and develop PKD models in C. elegans, zebrafish, rodents, and pig. Established models in C. elegans, zebrafish, and rodents are available for sharing or collaborative projects. Standardized protocols for zebrafish and murine preclinical testing are available for examining novel therapeutics. Highly conserved C. elegans and zebrafish models are options for higher throughput/lower cost drug screening. Within Imaging, we continue to develop advanced protocols for preclinical and clinical imaging (3D ultrasound, CT, quantitative MR), and image processing (radiomics, machine learning, and deep learning analysis). Standardized protocols are available for accurate and automated analysis of organ volume, cyst number, and size, providing enhanced patient-specific image-based metrics. We support numerous trainees spanning undergraduate through junior faculty, including Summer Undergraduate Research Fellowships available through an R25 grant and Postdoctoral Fellowships available through a T-32 grant.

Abstract: INFO17

Mayo Clinic Translational Polycystic Kidney Disease Center (MTPC)

Session Information

  • Informational Posters
    November 05, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
    Abstract Time: 10:00 AM - 12:00 PM

Category:

  • No subcategory defined

Authors

  • Sussman, Caroline R., Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Senum, Sarah R., Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Gregory, Adriana, Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Li, Xiaoyan, Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Mann, Zoey, Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Sieben, Cynthia J., Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Yang, Hana, Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Kennedy, Kristian M., Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Romero, Michael F., Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Chebib, Fouad T., Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Irazabal, Maria V., Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Li, Xiaogang, Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Erickson, Bradley J., Mayo Clinic Department of Radiology, Rochester, Minnesota, United States
  • Hu, Jinghua, Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Kline, Timothy L., Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Torres, Vicente E., Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Harris, Peter C., Mayo Clinic Department of Nephrology and Hypertension, Rochester, Minnesota, United States
Description

The Mayo Clinic Translational PKD Center is comprised of faculty and staff with expertise spanning basic research through clinical trials. Our collaborative efforts provide insights into PKD pathomechanisms for biomarker, therapy, and prognostics development, and we share materials, resources, and expertise to support academic and industry-sponsored PKD research. Our goal is to promote basic research breakthroughs and facilitate their translation into clinical practice. The Center has three areas of focus: 1) Genetics, Epigenetics and Metabolomics (GEM), 2) Model Systems, and 3) Imaging. Within GEM, our expertise and resources include genetic characterization of PKD patients and elucidation of epi/genetic and cellular mechanisms of PKD for therapy and biomarker discovery. We maintain a Cystic Kidney and Liver Disease Biobank that collects and shares PKD patient materials. With PKD Foundation support, we maintain the PKD Foundation ADPKD Mutation Database, which collates and evaluates the significance of variants in the PKD1 and PKD2 genes to aid diagnostics and categorization of patient populations. Within Model Systems, we maintain and develop PKD models in C. elegans, zebrafish, rodents, and pig. Established models in C. elegans, zebrafish, and rodents are available for sharing or collaborative projects. Standardized protocols for zebrafish and murine preclinical testing are available for examining novel therapeutics. Highly conserved C. elegans and zebrafish models are options for higher throughput/lower cost drug screening. Within Imaging, we continue to develop advanced protocols for preclinical and clinical imaging (3D ultrasound, CT, quantitative MR), and image processing (radiomics, machine learning, and deep learning analysis). Standardized protocols are available for accurate and automated analysis of organ volume, cyst number, and size, providing enhanced patient-specific image-based metrics. We support numerous trainees spanning undergraduate through junior faculty, including Summer Undergraduate Research Fellowships available through an R25 grant and Postdoctoral Fellowships available through a T-32 grant.